Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData Read more
Sentynl completes asset transfer of CUTX-101 Copper Histidinate product candidate for treatment of Menkes Disease from Cyprium Read more
Non-stimulants face uphill battle to penetrate ADHD market despite lower abuse potential: GlobalData Read more
